癌症研究
下调和上调
生物
基因
突变
表型
组蛋白
DNA修复
化疗
肺癌
DNA损伤
同源重组
合成致死
糖酵解
乙酰化
基因表达调控
基因表达
转染
DNA甲基化
癌症
细胞
清脆的
体内
细胞培养
DNA
表观遗传学
细胞生长
抑癌基因
小RNA
遗传增强
细胞毒性T细胞
分子生物学
医学
程序性细胞死亡
作者
Scott Best,Daniel S. Hippe,Eli Grunblatt,Jackson P. Fatherree,Pritha Chanana,Feinan Wu,Richard G. Ivey,Jacob J. Kennedy,David Sokolov,Ali Ibrahim,Haodong Xu,Raymond J. Monnat,Lucas B. Sullivan,Patrick J. Paddison,Amanda G. Paulovich,David P MacPherson
标识
DOI:10.1038/s41467-026-75117-2
摘要
Small cell lung cancer (SCLC) responds exceptionally well to cytotoxic chemotherapy. However, relapse with the emergence of chemoresistant disease is rapid and accompanied by poor treatment outcomes. To understand the genetic basis of chemoresistance in SCLC, we apply in vivo CRISPR deletion screening to patient-derived xenograft (PDX) models. Top screen hits include genes encoding components of the transcriptional co-activator SAGA (Spt-Ada-Gcn5 acetyltransferase) complex. We demonstrate that deletion of the SAGA deubiquitylase USP22 confers cisplatin-etoposide resistance in two chemosensitive PDX models, and that restoring expression in a PDX model harboring homozygous truncating mutation of USP22 re-sensitizes tumors to chemotherapy. USP22 loss increases gene body histone H2AK119 monoubiquitylation at key regulators of neuronal differentiation and suppresses neural and neuroendocrine gene expression including targets of ASCL1. Chemoresistance following USP22 loss reflects attenuated DNA damage-driven phosphorylation events and apoptosis, in conjunction with increased expression of glycolysis and hypoxia-related genes. Glycolysis program upregulation may reflect a targetable vulnerability, as inhibition of GLUT1 re-sensitizes USP22-null tumors to chemotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI